Canada Royal Enoch Phytomedicine Ltd., a pioneering force in ginseng and ginsenoside research, proudly announces a historic milestone: its premium ginsenoside supplement, Redsenol-1 Plus Noble Ginsenosides, has been officially included in the U.S. National Cancer Institute’s (NCI) Drug Dictionary. This distinction makes Redsenol-1 Plus the first and only product in the global multi-component ginsenoside industry to receive this listing.
Why This Matters: NCI Drug Dictionary Recognition
The NCI Drug Dictionary serves as a gold-standard reference for drugs and agents used in cancer treatment and supportive care. This authoritative database now defines Redsenol-1 Plus as an oral herbal supplement containing sixteen bioactive ginsenosides—including Rg3(R, S), Rh1(S, R), Rh2(R, S), Rk1, Rk3, and more.
What sets Redsenol-1 Plus apart from conventional ginseng extract supplements? Unlike most products that contain large-molecule, poorly absorbed ginsenosides such as Rg1, Rb1, and Rc, Redsenol-1 Plus is formulated with 16 highly bioavailable rare ginsenosides at a concentration of 20%—five times higher than traditional ginseng extracts.
Leading Innovation in Ginsenoside Science
Through proprietary extraction, processing, and transformation technologies, Canada Royal Enoch Phytomedicine has achieved large-scale production of these rare and valuable compounds. This breakthrough positions the company at the forefront of global ginsenoside innovation.
“The inclusion of Redsenol-1 Plus in the NCI Drug Dictionary provides a standardized reference for researchers and clinicians worldwide,” says Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine. “We are committed to advancing scientific understanding of ginsenosides in oncology and beyond.”
Ongoing Clinical Research on Cancer-Related Fatigue
The NCI recognition comes as Canada Royal Enoch Phytomedicine continues its groundbreaking clinical trial on cancer-related fatigue (ClinicalTrials.gov Identifier: NCT05664009). Conducted by KGK Science, Inc., a leading Canadian clinical research organization, this triple-blind, placebo-controlled study investigates the effectiveness of Redsenol-1 Plus in alleviating fatigue—a debilitating symptom experienced by many cancer patients.
 Drug Dictionary, setting a new standard in oncology support.){kind=link}